Hiroyuki Yoda • UCSF Profiles (original) (raw)

  1. Myeloid-targeting immunotherapies overcome inhibitory barriers in immune-evasive neuroblastoma. J Exp Med. 2025 Sep 01; 222(9). Ménard M, Yoda H, Nasholm N, Barata MJ, Wang L, Simonds EF, Lu ED, Wong-Michalak S, McHenry L, Farrel A, Kaufman R, Lopez V, Kennedy RJ, Fernandez GE, Shimada H, Grossmann LD, Asgharzadeh S, Maris JM, Gustafson WC, Weiss WA. PMID: 40658105; PMCID: PMC12263170.
    View in: PubMed Mentions: Fields:
    Translation:HumansAnimalsCells
  2. ATR Inhibition Synergizes With Alkylating PI Polyamide Targeting MYCN by Suppressing DNA Repair in MYCN-Amplified Neuroblastoma. Cancer Sci. 2025 Jun; 116(6):1691-1702. Lai X, Yoda H, Qiao Y, Kida Y, Takenaga K, Shinozaki Y, Koshikawa N, Takatori A. PMID: 40052411; PMCID: PMC12127093.
    View in: PubMed Mentions: 1 Fields:
    Translation:HumansAnimalsCells
  3. EGFR and EGFRvIII coopt host defense pathways promoting progression in glioblastoma. Neuro Oncol. 2025 Feb 10; 27(2):383-397. An Z, Fan QW, Wang L, Yoda H, Barata MJ, Jimenez-Morales D, Phillips JJ, Swaney DL, Stevenson E, Lee E, Krogan N, Weiss WA. PMID: 39248287; PMCID: PMC11812036.
    View in: PubMed Mentions: 1 Fields:
    Translation:HumansAnimalsCells
  4. Poly (ADP-ribose) polymerase inhibitor sensitized DNA damage caused by an alkylating pyrrole-imidazole polyamide targeting MYCN in neuroblastoma cells. Biochem Biophys Res Commun. 2024 11 26; 735:150794. Lai X, Yoda H, Qiao Y, Kida Y, Takenaga K, Shinozaki Y, Koshikawa N, Takatori A. PMID: 39395371.
    View in: PubMed Mentions: 2 Fields:
    Translation:HumansCells
  5. ALK upregulates POSTN and WNT signaling to drive neuroblastoma. Cell Rep. 2024 03 26; 43(3):113927. Huang M, Fang W, Farrel A, Li L, Chronopoulos A, Nasholm N, Cheng B, Zheng T, Yoda H, Barata MJ, Porras T, Miller ML, Zhen Q, Ghiglieri L, McHenry L, Wang L, Asgharzadeh S, Park J, Gustafson WC, Matthay KK, Maris JM, Weiss WA. PMID: 38451815; PMCID: PMC11101011.
    View in: PubMed Mentions: 6 Fields:
    Translation:HumansCells
  6. Use of DNA-alkylating pyrrole-imidazole polyamides for anti-cancer drug sensitivity screening in pancreatic ductal adenocarcinoma. Cancer Med. 2023 03; 12(5):5821-5832. Tsujimoto A, Matsuo N, Lai X, Inoue T, Yoda H, Lin J, Shinozaki Y, Watanabe T, Koshikawa N, Takatori A, Nagase H. PMID: 36262061; PMCID: PMC10028039.
    View in: PubMed Mentions: 1 Fields:
    Translation:HumansAnimals
  7. CD55, a potential immunotherapeutic target for MYCN-amplified neuroblastoma. Neuro Oncol. 2022 06 01; 24(6):886-887. Yoda H, Weiss WA. PMID: 35090034; PMCID: PMC9159426.
    View in: PubMed Mentions: Fields:
    Translation:HumansCells
  8. Targeting anaplastic lymphoma kinase (ALK) gene alterations in neuroblastoma by using alkylating pyrrole-imidazole polyamides. PLoS One. 2021; 16(9):e0257718. Ota Y, Yoda H, Inoue T, Watanabe T, Shinozaki Y, Takatori A, Nagase H. PMID: 34591871; PMCID: PMC8483358.
    View in: PubMed Mentions: 2 Fields:
    Translation:HumansAnimalsCells
  9. CD133 prevents colon cancer cell death induced by serum deprivation through activation of Akt-mediated protein synthesis and inhibition of apoptosis. FEBS Open Bio. 2021 05; 11(5):1382-1394. Mori Y, Takeuchi A, Miyagawa K, Yoda H, Soda H, Nabeya Y, Watanabe N, Ozaki T, Shimozato O. PMID: 33720534; PMCID: PMC8091590.
    View in: PubMed Mentions: 7 Fields:
    Translation:HumansCells
  10. An expanded universe of cancer targets. Cell. 2021 03 04; 184(5):1142-1155. Hahn WC, Bader JS, Braun TP, Califano A, Clemons PA, Druker BJ, Ewald AJ, Fu H, Jagu S, Kemp CJ, Kim W, Kuo CJ, McManus M, B Mills G, Mo X, Sahni N, Schreiber SL, Talamas JA, Tamayo P, Tyner JW, Wagner BK, Weiss WA, Gerhard DS, Cancer Target Discovery and Development Network. PMID: 33667368; PMCID: PMC8066437.
    View in: PubMed Mentions: 101 Fields:
    Translation:HumansAnimals
  11. Targeting the mutant PIK3CA gene by DNA-alkylating pyrrole-imidazole polyamide in cervical cancer. Cancer Sci. 2021 Mar; 112(3):1141-1149. Krishnamurthy S, Yoda H, Hiraoka K, Inoue T, Lin J, Shinozaki Y, Watanabe T, Koshikawa N, Takatori A, Nagase H. PMID: 33377228; PMCID: PMC7935806.
    View in: PubMed Mentions: 12 Fields:
    Translation:HumansAnimalsCells
  12. Vitamin K3 derivative induces apoptotic cell death in neuroblastoma via downregulation of MYCN expression. Biochem Biophys Rep. 2019 Dec; 20:100701. Yoda H, Nakayama T, Miura M, Toriyama M, Motohashi S, Suzuki T. PMID: 31844686; PMCID: PMC6895568.
    View in: PubMed Mentions: 3
  13. PTPRK suppresses progression and chemo-resistance of colon cancer cells via direct inhibition of pro-oncogenic CD133. FEBS Open Bio. 2019 05; 9(5):935-946. Matsushita M, Mori Y, Uchiumi K, Ogata T, Nakamura M, Yoda H, Soda H, Takiguchi N, Nabeya Y, Shimozato O, Ozaki T. PMID: 30947381; PMCID: PMC6487712.
    View in: PubMed Mentions: 8 Fields:
    Translation:HumansCells
  14. Estimating genome-wide off-target effects for pyrrole-imidazole polyamide binding by a pathway-based expression profiling approach. PLoS One. 2019; 14(4):e0215247. Lin J, Krishnamurthy S, Yoda H, Shinozaki Y, Watanabe T, Koshikawa N, Takatori A, Horton P, Nagase H. PMID: 30964912; PMCID: PMC6456183.
    View in: PubMed Mentions: 3 Fields:
    Translation:HumansAnimalsCells
  15. Direct Targeting of MYCN Gene Amplification by Site-Specific DNA Alkylation in Neuroblastoma. Cancer Res. 2019 02 15; 79(4):830-840. Yoda H, Inoue T, Shinozaki Y, Lin J, Watanabe T, Koshikawa N, Takatori A, Nagase H. PMID: 30584073.
    View in: PubMed Mentions: 28 Fields:
    Translation:HumansAnimalsCells
  16. Depletion of runt-related transcription factor 2 (RUNX2) enhances SAHA sensitivity of p53-mutated pancreatic cancer cells through the regulation of mutant p53 and TAp63. PLoS One. 2017; 12(7):e0179884. Ogata T, Nakamura M, Sang M, Yoda H, Hiraoka K, Yin D, Sang M, Shimozato O, Ozaki T. PMID: 28671946; PMCID: PMC5495219.
    View in: PubMed Mentions: 1 Fields:
    Translation:HumansCells
  17. Depletion of pro-oncogenic RUNX2 enhances gemcitabine (GEM) sensitivity of p53-mutated pancreatic cancer Panc-1 cells through the induction of pro-apoptotic TAp63. Oncotarget. 2016 Nov 01; 7(44):71937-71950. Ozaki T, Nakamura M, Ogata T, Sang M, Yoda H, Hiraoka K, Sang M, Shimozato O. PMID: 27713122; PMCID: PMC5342134.
    View in: PubMed Mentions: 6 Fields:
    Translation:HumansCells
  18. Improvement of gemcitabine sensitivity of p53-mutated pancreatic cancer MiaPaCa-2 cells by RUNX2 depletion-mediated augmentation of TAp73-dependent cell death. Oncogenesis. 2016 Jun 13; 5(6):e233. Nakamura M, Sugimoto H, Ogata T, Hiraoka K, Yoda H, Sang M, Sang M, Zhu Y, Yu M, Shimozato O, Ozaki T. PMID: 27294865; PMCID: PMC4945741.
    View in: PubMed Mentions: 11
  19. Silencing of RUNX2 enhances gemcitabine sensitivity of p53-deficient human pancreatic cancer AsPC-1 cells through the stimulation of TAp63-mediated cell death. Cell Death Discov. 2015; 1:15010. Sugimoto H, Nakamura M, Yoda H, Hiraoka K, Shinohara K, Sang M, Fujiwara K, Shimozato O, Nagase H, Ozaki T. PMID: 27551445; PMCID: PMC4981025.
    View in: PubMed Mentions: 14
  20. Inhibition of KRAS codon 12 mutants using a novel DNA-alkylating pyrrole-imidazole polyamide conjugate. Nat Commun. 2015 Apr 27; 6:6706. Hiraoka K, Inoue T, Taylor RD, Watanabe T, Koshikawa N, Yoda H, Shinohara K, Takatori A, Sugimoto H, Maru Y, Denda T, Fujiwara K, Balmain A, Ozaki T, Bando T, Sugiyama H, Nagase H. PMID: 25913614.
    View in: PubMed Mentions: 39 Fields:
    Translation:HumansAnimalsCells
  21. Runt-related transcription factor 2 attenuates the transcriptional activity as well as DNA damage-mediated induction of pro-apoptotic TAp73 to regulate chemosensitivity. FEBS J. 2015 Jan; 282(1):114-28. Ozaki T, Sugimoto H, Nakamura M, Hiraoka K, Yoda H, Sang M, Fujiwara K, Nagase H. PMID: 25331851; PMCID: PMC4368372.
    View in: PubMed Mentions: 20 Fields:
    Translation:HumansCells
  22. Vitamin K3 analogs induce selective tumor cytotoxicity in neuroblastoma. Biol Pharm Bull. 2012; 35(4):617-23. Kitano T, Yoda H, Tabata K, Miura M, Toriyama M, Motohashi S, Suzuki T. PMID: 22466570.
    View in: PubMed Mentions: 11 Fields:
    Translation:HumansCells

This graph shows the number and percent of publications by field. Fields are based on how the National Library of Medicine (NLM) classifies the publications' journals and might not represent the specific topics of the publications. Note that an individual publication can be assigned to more than one field. As a result, the publication counts in this graph might add up to more than the number of publications the person has written. To see the data as text, click here.

This graph shows the number and percent of publications by field. Fields are based on how the National Library of Medicine (NLM) classifies the publications' journals and might not represent the specific topics of the publications. Note that an individual publication can be assigned to more than one field. As a result, the publication counts in this graph might add up to more than the number of publications the person has written. To see the data as text, click here.

Start with: newest oldestInclude: line numbers double spacing all authors publication IDs